Investigating the Anti-diabetic and Lipid-regulating Properties of Eclipta alba in Alloxan-induced Diabetes

Since the dawn of human civilization, humanity has used herbal medicine for medicinal purposes. Traditional medicine has experienced a substantial surge in popularity in recent years. This research sought to evaluate the antidiabetic effectiveness and lipid profile of Eclipta alba. We evaluated the antidiabetic efficacy using the alloxan-induced diabetic model. The dosages of 800 mg/kg and 1200 mg/kg in groups 5 and 6, respectively, yielded statistically significant findings (p < 0.05) regarding antidiabetic efficacy. The group receiving a 1200 mg/kg dosage had statistically significant outcomes for total cholesterol and LDL, with findings of 196.15 ± 8.91* and 123.77 ± 6.50*, respectively (p < 0.05). However, no groups exhibited statistically significant results for HDL and triglyceride levels, despite a reduction in these parameters in the blood after the administration of the extract. Group 6, with a dosage of 1200 mg/kg, exhibited statistically significant results (p < 0.05) for SGPT and SGOT, with values of 88.71 ± 6.23* and 92.82 ± 7.50*, respectively. In the kidney function test, groups 5 and 6 exhibited statistically significant results (p < 0.05) at doses of 800 and 1200 mg/kg. So ethanolic extract of this plant shows significant antidiabetic and antihyperlipidemic activity and further advanced research on this plant may add alternative medicine to the treatment system.